Overall clinical experience with aztreonam in the treatment of intraabdominal infections.
Response to aztreonam (1-2 g administered intravenously three or four times daily) was evaluated in a multiclinic study of 113 patients with intraabdominal infections due to gram-negative aerobic organisms. Appropriate therapy with an antibiotic (usually clindamycin) active against gram-positive and/or anaerobic organisms was administered concomitantly for mixed-pathogen infections. A favorable clinical response and microbiologic cure occurred in 90% of the patients treated. All of the 13 patients with infections due to Pseudomonas aeruginosa responded clinically, and 11 of the 13 patients experienced microbiologic cure. In a comparative study, 59 patients were treated with aztreonam and 56 were treated with tobramycin (3-5 mg/kg per day); 95% of the patients in the aztreonam group and 81% of those in the tobramycin group experienced microbiologic cure.
D000005:Abdomen; D000038:Abscess / Q000188:drug therapy; D001398:Aztreonam / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006088:Gram-Negative Aerobic Bacteria; D006801:Humans; D010538:Peritonitis / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D014031:Tobramycin / Q000627:therapeutic use
D001398:Aztreonam; D014031:Tobramycin